Franklin Resources
KPTI icon

Franklin Resources’s Karyopharm Therapeutics KPTI Stock Holding History

Franklin Resources’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,376
Closed -$70.2K – 2357
2022
Q4 		$70.2K Hold
1,376
– – ﹤0.01% 2171
2022
Q3 		$112K Buy
+1,376
New +$103K ﹤0.01% 2087
2019
Q2 		– Sell
-2,591
Closed -$227K – 1563
2019
Q1 		$227K Sell
2,591
-117,389
-98% -$13M ﹤0.01% 1439
2018
Q4 		$16.9M Sell
119,980
-2,688
-2% -$453K 0.01% 761
2018
Q3 		$31.3M Sell
122,668
-17,549
-13% -$4.85M 0.02% 654
2018
Q2 		$35.7M Buy
140,217
+3,418
+2% +$845K 0.02% 617
2018
Q1 		$27.5M Sell
136,799
-85,706
-39% -$17.1M 0.01% 694
2017
Q4 		$32M Buy
222,505
+13,354
+6% +$2.14M 0.02% 673
2017
Q3 		$34.4M Buy
209,151
+2,329
+1% +$334K 0.02% 639
2017
Q2 		$28.1M Sell
206,822
-3,063
-1% -$453K 0.01% 699
2017
Q1 		$40.4M Sell
209,885
-5,528
-3% -$887K 0.02% 581
2016
Q4 		$30.4M Sell
215,413
-3,068
-1% -$415K 0.02% 674
2016
Q3 		$31.9M Sell
218,481
-61
-0% -$7.33K 0.02% 674
2016
Q2 		$22M Sell
218,542
-67,071
-23% -$8.71M 0.01% 779
2016
Q1 		$38.2M Sell
285,613
-58,985
-17% -$6.51M 0.02% 608
2015
Q4 		$68.5M Sell
344,598
-29,717
-8% -$6.43M 0.03% 460
2015
Q3 		$59.1M Buy
374,315
+60,443
+19% +$16.2M 0.03% 498
2015
Q2 		$128M Sell
313,872
-9,411
-3% -$4.07M 0.06% 328
2015
Q1 		$148M Buy
323,283
+13,099
+4% +$5.65M 0.07% 288
2014
Q4 		$174M Buy
310,184
+15,517
+5% +$8.81M 0.08% 252
2014
Q3 		$154M Buy
294,667
+11,804
+4% +$6.66M 0.07% 271
2014
Q2 		$198M Buy
282,863
+148,989
+111% +$69.3M 0.09% 244
2014
Q1 		$62M Buy
133,874
+81,414
+155% +$41.3M 0.03% 514
2013
Q4 		$18M Buy
+52,460
New +$14.5M 0.01% 841

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources's KPTI Position: Q1 2023 in Review

Franklin Resources sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 1,376 shares — an estimated $70.2K sold.

Franklin Resources first reported a position in KPTI in Q4 2013 and held it in 24 quarters. The position peaked at $198M in Q2 2014. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • Franklin Resources reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Franklin Resources sold 1,376 Karyopharm Therapeutics shares in Q1 2023, an estimated $70.2K.
  • Franklin Resources first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 24 quarters.
  • Franklin Resources's Karyopharm Therapeutics position peaked at $198M in Q2 2014.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Franklin Resources's 13F filing for Q1 2023, filed 12 May 2023.